Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Liberation Of Soluble Urokinase Plasminogen Receptor (supar) Occurs In Response To Coronavirus Infection But Not To Influenza Virus Infection
    Sharma, Sriganesh B.
    Kumar, Kiran
    Wu, Weisheng
    Hayek, Salim S.
    Moore, Bethany B.
    Obi, Andrea T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [32] Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behcet's disease and correlation with disease activity
    Saylam Kurtipek, Gulcan
    Kesli, Recep
    Tuncez Akyurek, Fatma
    Akyurek, Fikret
    Ataseven, Arzu
    Terzi, Yuksel
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (04) : 866 - 870
  • [33] Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome
    Hoenigl, Martin
    Raggam, Reinhard B.
    Wagner, Jasmin
    Valentin, Thomas
    Leitner, Eva
    Seeber, Katharina
    Zollner-Schwetz, Ines
    Krammer, Werner
    Prueller, Florian
    Grisold, Andrea J.
    Krause, Robert
    CLINICAL BIOCHEMISTRY, 2013, 46 (03) : 225 - 229
  • [34] Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
    Wittenhagen, Per
    Andersen, Jesper Brandt
    Hansen, Anita
    Lindholm, Lone
    Ronne, Frederik
    Theil, Jorn
    Tvede, Michael
    Eugen-Olsen, Jesper
    BIOMARKER INSIGHTS, 2011, 6 : 79 - 82
  • [35] Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
    Vassiliou, Alice G.
    Zacharis, Alexandros
    Vrettou, Charikleia S.
    Keskinidou, Chrysi
    Jahaj, Edison
    Mastora, Zafeiria
    Orfanos, Stylianos E.
    Dimopoulou, Ioanna
    Kotanidou, Anastasia
    DIAGNOSTICS, 2022, 12 (05)
  • [36] The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
    Scharrenberg, Jan Simon
    Yagdiran, Ayla
    Brinkmann, Julia
    Brune, Maik
    Siewe, Jan
    Jung, Norma
    Mahabir, Esther
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2019, 14 (01)
  • [37] Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes
    Theilade, S.
    Lyngbaek, S.
    Hansen, T. W.
    Eugen-Olsen, J.
    Fenger, M.
    Rossing, P.
    Jeppesen, J. L.
    JOURNAL OF INTERNAL MEDICINE, 2015, 277 (03) : 362 - 371
  • [38] Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
    Gumus, Aziz
    Altintas, Nejat
    Cinarka, Halit
    Kirbas, Aynur
    Haziroglu, Muge
    Karatas, Mevlut
    Sahin, Unal
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 357 - 365
  • [39] Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality
    Tornkovist, Peter B. S.
    Haupt, Thomas H.
    Rasmussen, Line J. H.
    Ladelundl, Steen
    Toft, Ulla
    Pisinger, Charlotta
    Eugen-Olsen, Jesper
    BRITISH JOURNAL OF NUTRITION, 2019, 121 (06) : 699 - 708
  • [40] Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
    Mehta, Anurag
    Desai, Shivang R.
    Ko, Yi-An
    Liu, Chang
    Dhindsa, Devinder S.
    Nayak, Aditi
    Hooda, Ananya
    Martini, Mohamed A.
    Ejaz, Kiran
    Sperling, Laurence S.
    Reiser, Jochen
    Hayek, Salim S.
    Quyyumi, Arshed A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05):